Alan Dunton - Palatin Technologies Independent Director
| PTN Stock | USD 1.08 0.07 6.09% |
Director
Dr. Alan William Dunton M.D. is Independent Director of the Company. He was senior vice president of research and development for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. Previously he was president of Danerius, LLC, a biotechnology consulting company, which he founded in 2006. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded company Oragenics, Inc. He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation, Adams Respiratory Therapeutics, Inc., MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York HospitalCornell University Medical Center. since 2011.
| Age | 64 |
| Tenure | 13 years |
| Address | Cedar Brook Corporate Center, Cranbury, NJ, United States, 08512 |
| Phone | 609 495 2200 |
| Web | https://palatin.com |
Palatin Technologies Management Efficiency
The company has Return on Asset of (1.3196) % which means that on every $100 spent on assets, it lost $1.3196. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.232) %, meaning that it generated no profit with money invested by stockholders. Palatin Technologies' management efficiency ratios could be used to measure how well Palatin Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of December 2024, Return On Equity is likely to grow to 280.03, though Return On Tangible Assets are likely to grow to (2.63). As of the 4th of December 2024, Non Current Assets Total is likely to grow to about 1.9 M, while Total Assets are likely to drop about 10.2 M.Similar Executives
| Found 2 records | DIRECTOR Age | ||
| Susan Berland | Senti Biosciences | 69 | |
| Mark Ternouth | Virax Biolabs Group | 56 | |
Management Performance
| Return On Equity | -6.23 | ||||
| Return On Asset | -1.32 |
Palatin Technologies Leadership Team
Elected by the shareholders, the Palatin Technologies' board of directors comprises two types of representatives: Palatin Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Palatin. The board's role is to monitor Palatin Technologies' management team and ensure that shareholders' interests are well served. Palatin Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Palatin Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, COO, CFO | ||
| Carl Spana, President, Chief Executive Officer, Director | ||
| Joseph Hull, Independent Director | ||
| Angela Rossetti, Independent Director | ||
| Robert Jordan, Senior Operations | ||
| Stephen Esq, Chief Officer | ||
| Burns McClellan, Vice Relations | ||
| John Dodd, Senior Development | ||
| Anthony Manning, Independent Director | ||
| Alan Dunton, Independent Director | ||
| Robert deVeer, Independent Director | ||
| MST CPA, COO, CFO | ||
| James Hattersley, Senior Development | ||
| John Prendergast, Co-Founder, Chairman and Chairman of Nominating and Corporate Governance Committee | ||
| Arlene Morris, Independent Director | ||
| Stephen Wills, Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary | ||
| Michael MD, Chief Officer |
Palatin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Palatin Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.23 | ||||
| Return On Asset | -1.32 | ||||
| Operating Margin | (23.79) % | ||||
| Current Valuation | 20.57 M | ||||
| Shares Outstanding | 19.55 M | ||||
| Shares Owned By Insiders | 3.50 % | ||||
| Shares Owned By Institutions | 7.88 % | ||||
| Number Of Shares Shorted | 1.17 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 15.83 X |
Pair Trading with Palatin Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Palatin Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Palatin Technologies will appreciate offsetting losses from the drop in the long position's value.Moving against Palatin Stock
The ability to find closely correlated positions to Palatin Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Palatin Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Palatin Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Palatin Technologies to buy it.
The correlation of Palatin Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Palatin Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Palatin Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Palatin Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palatin Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Palatin Stock, please use our How to Invest in Palatin Technologies guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palatin Technologies. If investors know Palatin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palatin Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.98) | Revenue Per Share 0.306 | Quarterly Revenue Growth (0.80) | Return On Assets (1.32) | Return On Equity (6.23) |
The market value of Palatin Technologies is measured differently than its book value, which is the value of Palatin that is recorded on the company's balance sheet. Investors also form their own opinion of Palatin Technologies' value that differs from its market value or its book value, called intrinsic value, which is Palatin Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palatin Technologies' market value can be influenced by many factors that don't directly affect Palatin Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palatin Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Palatin Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palatin Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.